Literature DB >> 20797561

Why we need clinical practice guidelines in chronic kidney disease.

Garabed Eknoyan1.   

Abstract

Clinical practice guidelines (CPGs) have become an essential, useful, and integral part of the practice of medicine in general and for the care of patients with chronic kidney disease (CKD) in particular. The reasons why CPGs have proven useful are related to the need of physicians, patients, and providers. Physician needs stem from the overwhelming amount of new information generated that requires systematic analysis, synthesis, and translation into specific clinically applicable recommendations. Patient needs arise from the desire of an increasingly well-informed public seeking evidence-based information in making joint decisions with their physicians. Provider needs derive from the necessity of appropriate criteria in assessing improved outcomes and in closing existing quality chasms in health care delivery. It is in the one patient one physician clinical encounter setting that guidelines are likely at their best in helping make appropriate decisions in each specific situation. All other uses of CPGs, no matter how meritorious, are secondary derivatives. Copyright 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20797561     DOI: 10.1053/j.jrn.2010.06.014

Source DB:  PubMed          Journal:  J Ren Nutr        ISSN: 1051-2276            Impact factor:   3.655


  2 in total

1.  Creating Shareable Clinical Decision Support Rules for a Pharmacogenomics Clinical Guideline Using Structured Knowledge Representation.

Authors:  Margaret K Linan; Davide Sottara; Robert R Freimuth
Journal:  AMIA Annu Symp Proc       Date:  2015-11-05

2.  Perceptions and use of the national kidney foundation KDOQI guidelines: a survey of U.S. renal healthcare providers.

Authors:  Michelle M Estrella; Bernard G Jaar; Kerri L Cavanaugh; Chester H Fox; Mark A Perazella; Sandeep S Soman; Emily Howell; Michael V Rocco; Michael J Choi
Journal:  BMC Nephrol       Date:  2013-10-24       Impact factor: 2.388

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.